BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Breda A, Konijeti R, Lam JS. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Review of Anticancer Therapy 2014;7:847-62. [DOI: 10.1586/14737140.7.6.847] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Shim M, Song C, Park S, Kim A, Choi S, Kim C, Ahn H. Hilar Location is an Independent Prognostic Factor for Recurrence in T1 Renal Cell Carcinoma After Nephrectomy. Ann Surg Oncol 2015;22:344-50. [DOI: 10.1245/s10434-014-4153-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
2 Griffin N, Grant LA, Bharwani N, Sohaib SA. Computed Tomography in Metastatic Renal Cell Carcinoma. Seminars in Ultrasound, CT and MRI 2009;30:359-66. [DOI: 10.1053/j.sult.2009.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
3 Wong K, Challacombe B. Better late than early for long-term survival in patients with recurrence after renal carcinoma. BJU Int 2013;112:877-8. [PMID: 24118953 DOI: 10.1111/bju.12324] [Reference Citation Analysis]
4 Lee LS, Tan M. Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol 2012;9:73-84. [DOI: 10.1038/nrurol.2011.224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 Juul S, Donskov F, Clark PE, Lund L, Azawi NH. GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. Int J Urol 2022. [PMID: 35362146 DOI: 10.1111/iju.14859] [Reference Citation Analysis]
6 Drosos K, Fischer K, Rieck G, Kälble T. [Retrovesical recurrence of renal cell carcinoma 14 years after laparoscopic nephrectomy: a case report]. Aktuelle Urol 2020. [PMID: 32894864 DOI: 10.1055/a-1200-3862] [Reference Citation Analysis]
7 Jin YL, Xin LM, Zhou CC, Ren Y. Polydatin exerts anti-tumor effects against renal cell carcinoma cells via induction of caspase-dependent apoptosis and inhibition of the PI3K/Akt pathway. Onco Targets Ther 2018;11:8185-95. [PMID: 30532558 DOI: 10.2147/OTT.S180785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ricciardulli S, Ding Q, Zhang X, Li H, Wang B, Yang G, Wang X, Zhang P, Ma X, Breda A. Evaluation of PADUA Score as Predictor of Warm Ischemia Time (WIT) during Laparoscopic Partial Nephrectomy (LPN). Urologia 2016;83:194-9. [DOI: 10.5301/uro.5000168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson E, Lam TBL, Marconi L, Fernandéz-Pello S, Nisen H, Meijer RP, Volpe A, Ljungberg B, Klatte T, Bensalah K, Dabestani S, Bex A. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy? BJU Int 2021;128:386-94. [PMID: 33794055 DOI: 10.1111/bju.15415] [Reference Citation Analysis]
10 Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol 2020;203:684-9. [PMID: 31596672 DOI: 10.1097/JU.0000000000000588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Review of Anticancer Therapy 2014;8:907-19. [DOI: 10.1586/14737140.8.6.907] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
12 Lam JS, Bergman J, Breda A, Schulam PG. Importance of surgical margins in the management of renal cell carcinoma. Nat Rev Urol 2008;5:308-17. [DOI: 10.1038/ncpuro1121] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
13 Dzimitrowicz H, Esterberg E, Miles L, Zanotti G, Borham A, Harrison MR. Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma. Cancer Med 2021. [PMID: 34751002 DOI: 10.1002/cam4.4407] [Reference Citation Analysis]
14 Wang W, Hu W, Wang Y, Yang J, Yue Z. MicroRNA-508 is downregulated in clear cell renal cell carcinoma and targets ZEB1 to suppress cell proliferation and invasion. Exp Ther Med 2019;17:3814-22. [PMID: 30988768 DOI: 10.3892/etm.2019.7332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, Bernstein M, Motzer RJ, Russo P. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011;185:433-438. [PMID: 21167521 DOI: 10.1016/j.juro.2010.09.100] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
16 Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; Members of the CORONA project and the SATURN project. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 2013;64:472-7. [PMID: 22748912 DOI: 10.1016/j.eururo.2012.06.030] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
17 Singh J, Jayaraj R, Baxi S, Mileva M, Skinner J, Dhand NK, Thomas M. Immunohistochemical expression levels of p53 and eIF4E markers in histologically negative surgical margins, and their association with the clinical outcome of patients with head and neck squamous cell carcinoma. Mol Clin Oncol 2016;4:166-72. [PMID: 26893854 DOI: 10.3892/mco.2015.689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
18 Patard J, Baumert H, Bensalah K, Bernhard J, Bigot P, Escudier B, Grenier N, Hétet J, Long J, Méjean A, Paparel P, Richard S, Rioux-leclercq N, Coloby P, Soulié M. Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein. Progrès en Urologie 2013;23:S177-204. [DOI: 10.1016/s1166-7087(13)70055-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
19 Patard J, Baumert H, Corréas J, Escudier B, Lang H, Long J, Neuzillet Y, Paparel P, Poissonnier L, Rioux-leclercq N, Soulié M. Recommandations en Onco-Urologie 2010 : Cancer du rein. Progrès en Urologie 2010;20:S319-39. [DOI: 10.1016/s1166-7087(10)70048-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
20 Azawi NH, Lund L, Fode M. Renal cell carcinomas mass of <4 cm are not always indolent. Urol Ann 2017;9:234-8. [PMID: 28794588 DOI: 10.4103/UA.UA_18_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Ha Y, Park YH, Kang SH, Hong S, Hwang T, Byun S, Kim Y. Predictive Factors for Late Recurrence in Patients With Stage T1 Clear Cell Renal Cell Carcinoma: A Multiinstitutional Study. Clinical Genitourinary Cancer 2013;11:51-5. [DOI: 10.1016/j.clgc.2012.08.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
22 Ronkainen H, Vaarala MH, Hirvikoski P, Ristimäki A. HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 2011;32:481-7. [PMID: 21161467 DOI: 10.1007/s13277-010-0141-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
23 Sun M, Vetterlein M, Harshman LC, Chang SL, Choueiri TK, Trinh QD. Risk Assessment in Small Renal Masses: A Review Article. Urol Clin North Am 2017;44:189-202. [PMID: 28411911 DOI: 10.1016/j.ucl.2016.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
24 Brookman-May SD, May M, Shariat SF, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project., Members of the SATURN-Project., Young Academic Urologists Renal Cancer Group. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int 2013;112:909-16. [PMID: 23890378 DOI: 10.1111/bju.12246] [Cited by in Crossref: 9] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rothberg MB, Peak TC, Reynolds CR, Hemal AK. Long-term oncologic outcomes of positive surgical margins following robot-assisted partial nephrectomy. Transl Androl Urol 2020;9:879-86. [PMID: 32420203 DOI: 10.21037/tau.2019.11.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K, Kristiansen G. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 2008;8:179. [PMID: 18582378 DOI: 10.1186/1471-2407-8-179] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]